The discovery of long acting β2-adrenoreceptor agonists

[1]  Michael H. Abraham,et al.  Hydrogen bonding. Part 9. Solute proton donor and proton acceptor scales for use in drug design , 1989 .

[2]  A. Bast,et al.  Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. , 1992, European journal of pharmacology.

[3]  R. A. Coleman,et al.  Investigations into factors determining the duration of action of the β2‐adrenoceptor agonist, salmeterol , 1993, British journal of pharmacology.

[4]  G. Anderson.  Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. , 1993, Life sciences.

[5]  K. Rabe,et al.  Why are long-acting beta-adrenoceptor agonists long-acting? , 1994, The European respiratory journal.

[6]  A. Taburet,et al.  Pharmacokinetic Optimisation of Asthma Treatment , 1994, Clinical pharmacokinetics.

[7]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[8]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .

[9]  A B Smith,et al.  An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex. , 1997, Journal of medicinal chemistry.

[10]  J. Lötvall,et al.  Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. , 1997, The European respiratory journal.

[11]  A. Tattersfield,et al.  The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects. , 1999, The European respiratory journal.

[12]  B. Waldeck.  Beta-adrenoceptor agonists and asthma--100 years of development. , 2002, European journal of pharmacology.

[13]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[14]  R. Austin,et al.  QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. , 2003, Journal of medicinal chemistry.

[15]  Paul A. Glossop,et al.  Progress in the Development of Inhaled, Long-Acting β2-Adrenoceptor Agonists , 2006 .